Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 mu g/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)

Singer Michael A.; Miller Dan M.; Gross Jeffrey G.; Greven Craig M.; Kapik Barry; Bailey Clare; Ghanchi Faruque; Kuppermann Baruch D.

首页> 外文期刊>Ophthalmic surgery, lasers & imaging retina >Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 mu g/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)

【24h】

Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 mu g/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)

机译：糖尿病黄斑水肿的视力结果与氟氨基酚醋酸盐0.2μg/天与Ranibizumab加延迟激光（DRCR协议I）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BACKGROUND AND OBJECTIVE: Visual outcomes of the FAME study (0.2 mu g/day fluocinolone acetonide [FAc]) and Protocol I (0.5 mg ranibizumab plus deferred laser) were compared using the area under the curve (AUG) analysis method.

机译：背景和目的：使用曲线下（八八）分析方法的面积进行比较了名称研究的视觉研究（0.2μg/日氟氨基醇氟喹啉酮[Flyocolone [Fac]）和方案I（0.5mg Ranibizumab加延迟激光）。

著录项

来源
《Ophthalmic surgery, lasers & imaging retina》 |2018年第9期|共9页
作者
Singer Michael A.; Miller Dan M.; Gross Jeffrey G.; Greven Craig M.; Kapik Barry; Bailey Clare; Ghanchi Faruque; Kuppermann Baruch D.;
展开▼
作者单位

Univ Texas Hlth Sci Ctr San Antonio San Antonio TX 78229 USA;

Cincinnati Eye Inst Cincinnati OH USA;

Carolina Retina Ctr Columbia SC USA;

Wake Forest Baptist Med Ctr Winston Salem NC USA;

Alimera Sci Alpharetta GA USA;

Univ Hosp Bristol NHS Fdn Trust Bristol Avon England;

Bradford Teaching Hosp NHS Fdn Trust Bradford W Yorkshire England;

UC Irvine Hlth Gavin Herbert Eye Inst Irvine CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
专利

1. Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 mu g/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I) [J] . Singer Michael A., Miller Dan M., Gross Jeffrey G., Ophthalmic surgery, lasers & imaging retina . 2018,第9期

机译：糖尿病黄斑水肿的视力结果与氟氨基酚醋酸盐0.2μg/天与Ranibizumab加延迟激光（DRCR协议I）
2. Progression of diabetic retinopathy in patients treated with 0.2 mu g/day fluocinolone acetonide (FAc) implants for diabetic macular edema (DME): a fellow eye controlled analysis [J] . Iezzi Raymond, Kapik Barry, Green Ken E. Investigative ophthalmology & visual science . 2017,第8期

机译：糖尿病患者患者的糖尿病视网膜病变患者进展嗜血糖酮（FAC）植入糖尿病性黄斑水肿（DME）：一种眼睛控制分析
3. The CONSTANT study: area-under-the-curve (AUC) analysis comparing fluocinolone acetonide 0.2 mu g/day (ILUVIEN (R)) implant with ranibizumab plus deferred laser over a 36-month study period [J] . Miller Daniel M. Investigative ophthalmology & visual science . 2017,第8期

机译：常数研究：面积曲线（AUC）分析比较氟氨基醇酮酮0.2μg/天（ILUVIEN）在36个月的研究期间用Ranibizumab加延迟激光植入
4. Prediction of visual acuity loss and indications for laser treatment in patients with diabetic macular edema using the Heidelberg Retina Tomograph. [D] . O'Neal, Dennis A. 2007

机译：使用海德堡视网膜断层扫描仪预测糖尿病性黄斑水肿患者的视力下降和激光治疗的适应症。
5. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema [O] . Susan B. Bressler, Adam Glassman, Talat Almukhtar, -1

机译：兰尼单抗提示或延缓激光治疗与糖尿病或曲安奈德加雷尼单抗治疗糖尿病性黄斑水肿的五年结果
6. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema [O] . Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland ( host institution ), Bressler, Susan B. ( author ), Glassman, Adam R. ( author ), 2016

机译：兰尼单抗及时或延缓激光治疗与糖尿病或曲安奈德加雷尼单抗治疗糖尿病性黄斑水肿的五年结果

Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 mu g/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I)

摘要

著录项

相似文献

相关主题

期刊订阅